Synthesis of 3-amino-5-nucleotide phosphamide and application of 3-amino-5-nucleotide phosphamide in oligonucleotide
By introducing phosphoramide-modified nucleotide structural units into oligonucleotide drugs, the problem of poor stability of oligonucleotides in the human body has been solved, achieving higher stability and bioactivity, and promoting the research and application of oligonucleotide drugs.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- SUZHOU SHENGNUOWEI BIOTECH CO LTD
- Filing Date
- 2025-12-11
- Publication Date
- 2026-05-12
AI Technical Summary
Traditional oligonucleotide drugs have poor stability in human serum and human liver microsomes and are easily degraded.
By using phosphoramide-modified nucleotide structural units, specific phosphoramide modifications are performed on nucleotide monomers through solid-phase synthesis to improve the stability and biological activity of oligonucleotides.
This improved the resistance to enzyme degradation and stability of oligonucleotides, resulting in superior pharmaceutical effects and providing a novel chemical modification strategy for the research and application of oligonucleotide drugs.
Smart Images
Figure CN122011070A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of oligonucleotide technology, specifically to the synthesis of 3´-amino-5´-nucleotide phosphoramide and its application in oligonucleotide drugs. Background Technology
[0002] Oligonucleotide drugs bind specifically to target genes through base complementarity, extending the target to upstream mRNA of pathogenic proteins and influencing target gene expression at the post-transcriptional level. Oligonucleotide drugs offer advantages such as abundant targets, high development success rates, short development cycles, and long-lasting efficacy, providing solutions for the treatment of many intractable diseases.
[0003] In addition, oligonucleotides are widely used in molecular biology research, disease diagnosis and treatment, such as as PCR primers, gene editing tools or targeted drugs.
[0004] Currently, oligonucleotide sequences synthesized from traditional nucleotide monomers have poor stability and are easily degraded in human serum and human liver microsomes.
[0005] In view of this, the present invention is hereby proposed. Summary of the Invention
[0006] The purpose of this invention is to provide a phosphoramide-modified oligonucleotide and its synthesis process. By preparing nucleotide phosphoramide, a specific phosphoramide-modified nucleotide structure is obtained, which can improve the stability and biological activity of the synthesized oligonucleotide.
[0007] In order to achieve the above-mentioned objectives of the present invention, the following technical solution is adopted: A first aspect of the present invention provides a phosphoramide-modified oligonucleotide, wherein the phosphoramide-modified oligonucleotide comprises at least one of the nucleotide structural units shown in Formula I, Formula II, Formula III or Formula IV: ...Formula I; ...Formula II; In Equations I and II: Base is a nucleotide base or its derivative, wherein the nucleotide base is adenine, guanine, cytosine, 5-methylcytosine, thymine, uracil, xanthine, hypoxanthine, pseudouracil, or N1-methylpseudorabies, etc., or its derivatives. R can be hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, or aromatic. R1 and R2 are alkyl, alkenyl, alkynyl, cycloalkyl, or aromatic groups, respectively; R3 is hydrogen, alkyl (including methyl, ethyl, long-chain alkyl), cycloalkyl, alkenyl, cycloalkenyl, alkynyl, silyl (including trimethylsilyl, triethylsilyl, triisopropylsilyl, tert-butyldimethylsilyl and tert-butyldiphenylsilyl), silyloxymethylene, alkoxyalkyl, benzyl or acyl (including acetyl, propionyl, butyryl, isobutyryl, benzoyl); ...Formula III; ...Form IV; In Equations III and IV: Base is a nucleotide base or its derivative, wherein the nucleotide base is adenine, guanine, cytosine, 5-methylcytosine, thymine, uracil, xanthine, hypoxanthine, pseudouracil, or N1-methylpseudorabies, etc., or its derivatives. R can be hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, or aromatic. R1 and R2 are alkyl, alkenyl, alkynyl, cycloalkyl, or aromatic groups, respectively; R4 and R5 are hydrogen, halogen, alkyl, cycloalkyl, alkoxyalkyl, alkenyl, cycloalkenyl, alkynyl, cyano, azide, amino (amino), mercapto, alkyl mercapto, selenyl, alkyl selenyl, etc., respectively.
[0008] The synthesis of the phosphoramide-modified oligonucleotides uses nucleotide monomers including those shown in Formula V or Formula VI: ...Form V; In formula V: Base is a nucleotide base containing a protecting group, such as adenine, guanine, cytosine, 5-methylcytosine, thymine, uracil, xanthine, hypoxanthine, pseudouracil, or N1-methylpseudorabies, and its derivatives. PG is triphenylmethyl, 4-methoxytriphenylmethyl, 4,4'-dimethoxytriphenylmethyl, 4,4',4''-trimethoxytriphenylmethyl, allyl, allyloxycarbonyl, benzyl, acyl, silyl (including trimethylsilyl, tert-butyldimethylsilyl or tert-butyldiphenylsilyl). R can be hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, or aromatic. R1 and R2 are alkyl, alkenyl, alkynyl, cycloalkyl, or aromatic groups, respectively; R3 is an alkyl group (including methyl, ethyl, long-chain alkyl), cycloalkyl, alkenyl, cycloalkenyl, alkynyl, silyl (including trimethylsilyl, triethylsilyl, triisopropylsilyl, tert-butyldimethylsilyl, tert-butyldiphenylsilyl), silyloxymethylene, alkoxyalkyl, benzyl, or acyl (including acetyl, propionyl, butyryl, isobutyryl, benzoyl). ...Form VI; In formula VI: Base is a nucleotide base containing a protecting group, such as adenine, guanine, cytosine, 5-methylcytosine, thymine, uracil, xanthine, hypoxanthine, pseudouracil, or N1-methylpseudorabies, and its derivatives. PG is triphenylmethyl, 4-methoxytriphenylmethyl, 4,4'-dimethoxytriphenylmethyl, 4,4',4''-trimethoxytriphenylmethyl, allyl, allyloxycarbonyl, benzyl, acyl, silyl (including trimethylsilyl, tert-butyldimethylsilyl or tert-butyldiphenylsilyl). R can be hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, or aromatic. R1 and R2 are alkyl, alkenyl, alkynyl, cycloalkyl, or aromatic groups, respectively. R4 and R5 are hydrogen, halogen, alkyl, cycloalkyl, alkoxyalkyl, alkenyl, cycloalkenyl, alkynyl, cyano, azide, amino (amino), mercapto, alkyl mercapto, selenyl, alkyl selenyl, etc., respectively.
[0009] Preferably, the protecting group is selected from one of triphenylmethyl, 4-methoxytriphenylmethyl, 4,4'-dimethoxytriphenylmethyl, 4,4',4''-trimethoxytriphenylmethyl, allyl, allyloxycarbonyl, benzyl, acyl, trimethylsilyl, tert-butyldimethylsilyl and tert-butyldiphenylsilyl.
[0010] Preferably, the nucleotide phosphoramide monomer comprises: , ; in: Base is a nucleotide base containing a protecting group, such as adenine, guanine, cytosine, 5-methylcytosine, thymine, uracil, xanthine, hypoxanthine, pseudouracil, or N1-methylpseudorabies, and its derivatives. R can be hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, or aromatic. R1 and R2 are alkyl, alkenyl, alkynyl, cycloalkyl, or aromatic groups, respectively. R3 is an alkyl group (including methyl, ethyl, long-chain alkyl), cycloalkyl, alkenyl, cycloalkenyl, alkynyl, silyl (including trimethylsilyl, triethylsilyl, triisopropylsilyl, tert-butyldimethylsilyl, tert-butyldiphenylsilyl), silyloxymethylene, alkoxyalkyl, benzyl, or acyl (including acetyl, propionyl, butyryl, isobutyryl, benzoyl). R4 and R5 are hydrogen, halogen, alkyl, cycloalkyl, alkoxyalkyl, alkenyl, cycloalkenyl, alkynyl, cyano, azide, amino (amino), mercapto, alkyl mercapto, selenyl, alkyl selenyl, etc., respectively.
[0011] Preferably, the nucleotide phosphoramide monomer comprises: , , , , , , , , , , , in: R can be hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, or aromatic. R1 and R2 are alkyl, alkenyl, alkynyl, cycloalkyl, or aromatic groups, respectively. R3 is an alkyl group (including methyl, ethyl, long-chain alkyl), cycloalkyl, alkenyl, cycloalkenyl, alkynyl, silyl (including trimethylsilyl, triethylsilyl, triisopropylsilyl, tert-butyldimethylsilyl and tert-butyldiphenylsilyl), silyloxymethylene, alkoxyalkyl, benzyl or acyl (including acetyl, propionyl, butyryl, isobutyryl, benzoyl).
[0012] Preferably, the nucleotide phosphoramide monomer comprises: , , , , , , , , , , , in: R can be hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, or aromatic. R1 and R2 are alkyl, alkenyl, alkynyl, cycloalkyl, or aromatic groups, respectively.
[0013] Preferably, the nucleotide phosphoramide monomer comprises: , , , , , , , , , , , in: R can be hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, or aromatic. R1 and R2 are alkyl, alkenyl, alkynyl, cycloalkyl, or aromatic groups, respectively.
[0014] Preferably, 4,4'-dimethoxytriphenylmethyl (DMTr) in the nucleotide monomer is replaced with triphenylmethyl (Tr), 4-methoxytriphenylmethyl (MMTr), or 4,4',4''-trimethoxytriphenylmethyl (TMTr).
[0015] Preferably, the nucleotide monomer is prepared by reacting a nucleotide containing a protecting group (N3') with phosphoramide dichloride in the liquid phase.
[0016] The modified oligonucleotides proposed in this invention contain phosphoramide-modified nucleotide structures that can improve the biostability and anti-enzymatic degradation activity of the oligonucleotides.
[0017] A second aspect of the present invention provides a synthetic process for the above-mentioned phosphoramide-modified oligonucleotide, wherein the coupling of nucleotide monomers in the solid-phase synthesis is in a 5' to 3' direction, and the synthetic process includes the following steps: (a) Load nucleotide monomers onto a solid support, then remove the 3' protecting group from the nucleotide monomers and wash them; (b) A nucleotide monomer is pumped into the washed system for coupling, followed by capping, removal of the 3' protecting group on the nucleotide monomer, and washing. The nucleotide monomer is a phosphoramide nucleotide monomer or a phosphorous acid nucleotide monomer. If the nucleotide monomer is a phosphorous acid nucleotide monomer, after the coupling reaction, the trivalent phosphite is converted to a pentavalent phosphate ester by oxidation or sulfidation, followed by capping, removal of the 3' protecting group on the nucleotide monomer, and washing. (c) Repeat step (b) to obtain oligonucleotides with phosphoramide-modified nucleotide structures.
[0018] Compared with the prior art, the beneficial effects of the present invention include at least the following: This invention achieves the preparation of oligonucleotides containing phosphoramide structural units by specifically defining the structure of phosphoramide-modified nucleotide monomers. Compared with traditional oligonucleotide molecules, the phosphoramide-modified oligonucleotide drugs proposed in this invention have superior pharmaceutical effects in terms of anti-enzymatic degradation, stability, and binding, providing a novel chemical modification strategy for the research and application of oligonucleotide drugs. Detailed Implementation
[0019] The embodiments of the technical solution of the present invention will be described in detail below with reference to the examples. The following embodiments are only used to illustrate the technical solution of the present invention more clearly, and are therefore only examples, and should not be used to limit the scope of protection of the present invention.
[0020] It should be noted that, unless otherwise stated, the technical or scientific terms used in this application should have the ordinary meaning as understood by one of ordinary skill in the art to which this invention pertains.
[0021] In this invention, the substances corresponding to the abbreviations are as follows: PS: Polystyrene; CPG: Controlled pore glass; DBU: 1,8-Dazabicycloundec-7-ene; P(III): Trivalent phosphorus (phosphine); P(V): Pentavalent phosphorus (phosphine); F: Fluorine; Me: Methyl; Alkyl: Alkyl; Allyl: Allyl; Alloc: Allyloxycarbonyl; Bn: Benzyl; Bz: Benzoyl; Tr: Triphenylmethyl; MMTr: Methoxytriphenylmethyl; DMTr: Dimethoxytriphenylmethyl; TMTr: Trimethoxytriphenylmethyl; iBu: 2-Isobutyryl; NPE: 4-Nitrophenylethoxy; Ph: Aromatic; TMS: Trimethylsilyl; TBDMS: Tert-butyldimethylsilyl; TBDPS: Tert-butyldiphenylsilyl; DCM: Dichloromethane; DMF: N,N-Dimethylformamide; DMAP: 4-Dimethylaminopyridine; TBAF: Tetrabutylammonium fluoride; THF: Tetrahydrofuran; TFA: Trifluoroacetic acid; iPrOH: Isopropanol; TLC: Thin-layer chromatography; A: Adenine; G: Guanine Guanine; C: Cytosine; T: Thymine; U: Uracil; I: Hypoxanthine; Xan: Xanthine; m5C: 5-methylcytosine; HPLC: High performance liquid chromatography.
[0022] Example 1 This embodiment describes a method for synthesizing a phosphoramide-modified oligonucleotide monomer, adenine phosphoramide, A-1:((2S,3R,4R,5R)-5-(6-benzamido-9H-purin-9-yl)-3-((bis(4-methoxyphenyl)(phenyl)methyl)amino)-4-methoxytetrahydrofuran-2-yl)methyldimethylphosphoramidochloridate. The synthetic reaction formula is as follows: ; Synthesis methods include: Under nitrogen protection, 687 mg of O2'-Me-N3'-DMTr-N6-Bz-A (A-0, 1.0 mmol, 1.0 eq.) was added to a dry mixed solvent (5 mL dichloromethane and 5 mL acetonitrile), and the temperature was maintained at 0 °C. Then, 174 mg of lithium bromide (2.0 mmol, 2.0 eq.) was added, and the mixture was stirred for 5 minutes. Subsequently, 0.30 mL of DBU (2.0 mmol, 2.0 eq.) and 0.18 mL of N,N-dimethylphosphoaminodichloride (1.5 mmol, 1.5 eq.) dissolved in 1 mL of dry dichloromethane were added. The mixture was stirred at 0 °C for 40 minutes under nitrogen protection. The solvent was removed under reduced pressure. 50 mL of ethyl acetate was added to the residue, followed by washing with 30 mL of cold water. The organic phase was dried over sodium sulfate and concentrated under reduced pressure. Separation was performed by silica gel chromatography with a mixed solvent of dichloromethane / acetone / methanol as the mobile phase, yielding 456 mg of the target product A-1 (purity above 99%, yield 56%).
[0023] Example 2 This embodiment describes a method for synthesizing a phosphoramide-modified oligonucleotide monomer, uracil phosphoramide, U-1-1:((2S,3R,4R,5R)-3-((bis(4-methoxyphenyl)(phenyl)methyl)amino)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-methoxytetrahydrofuran-2-yl)methyldimethylphosphoramidochloridate. The synthetic reaction formula is as follows: ; Synthesis methods include: Under nitrogen protection, 560 mg of O2'-Me-N3'-DMTr-U (U-1-0, 1.0 mmol, 1.0 eq.) was added to a dry mixed solvent (5 mL dichloromethane and 5 mL acetonitrile), and the temperature was maintained at 0 °C. Then, 174 mg of lithium bromide (2.0 mmol, 2.0 eq.) was added, and the mixture was stirred for 5 minutes. Next, 0.30 mL of DBU (2.0 mmol, 2.0 eq.) and 0.18 mL of N,N-dimethylphosphoaminodichloride (1.5 mmol, 1.5 eq.) dissolved in 1 mL of dry dichloromethane were added sequentially. The mixture was stirred at 0 °C for 40 minutes under nitrogen protection. The solvent was removed under reduced pressure. 50 mL of ethyl acetate was added to the residue, followed by washing with 30 mL of cold water. The organic phase was dried over sodium sulfate and concentrated under reduced pressure. Separation was performed by silica gel chromatography with a mixed solvent of dichloromethane / acetone / methanol as the mobile phase, yielding 433 mg of the target product U-1-1 (purity above 99%, yield 63%).
[0024] Furthermore, the following nucleotide monomers were prepared using the synthetic method described above: , , , , , , , , .
[0025] Example 3 This embodiment describes a method for synthesizing a phosphoramide-modified oligonucleotide monomer, uracil phosphoramide, U-2-1:((2S,3R,4R,5R)-3-((bis(4-methoxyphenyl)(phenyl)methyl)amino)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluorotetrahydrofuran-2-yl)methyldimethylphosphoramidochloridate. The synthetic reaction formula is as follows: ; Synthesis methods include: Under nitrogen protection, 548 mg of 2'-F-N3'-DMTr-U (U-2-0, 1.0 mmol, 1.0 eq.) was added to a dry mixed solvent (5 mL dichloromethane and 5 mL acetonitrile), and the temperature was maintained at 0 °C. Then, 174 mg of lithium bromide (2.0 mmol, 2.0 eq.) was added, and the mixture was stirred for 5 minutes. Next, 0.30 mL of DBU (2.0 mmol, 2.0 eq.) and 0.18 mL of N,N-dimethylphosphoaminodichloride (1.5 mmol, 1.5 eq.) dissolved in 1 mL of dry dichloromethane were added sequentially. The mixture was stirred at 0 °C for 40 minutes under nitrogen protection. The solvent was removed under reduced pressure. 50 mL of ethyl acetate was added to the residue, followed by washing with 30 mL of cold water. The organic phase was dried over sodium sulfate and concentrated under reduced pressure. Separation was performed by silica gel chromatography with a mixed solvent of dichloromethane / acetone / methanol as the mobile phase, yielding 446 mg of the target product U-2-1 (purity above 99%, yield 66%).
[0026] Furthermore, the following nucleotide monomers were prepared using the synthetic method described above: , , , , , , , , , .
[0027] Furthermore, the following nucleotide monomers were prepared using the synthetic method described above: , , , , , , , , , , .
[0028] Example 4 This embodiment describes a method for synthesizing a phosphoramide-modified oligonucleotide monomer, uracil phosphoramide, U-3-1:((2S,3R,4R,5R)-3-((bis(4-methoxyphenyl)(phenyl)methyl)(methyl)amino)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-methoxytetrahydrofuran-2-yl)methyldimethylphosphoramidochloridate. The synthetic reaction formula is as follows: ; Synthesis methods include: Under nitrogen protection, 574 mg of O2'-Me-N3'-Me-N3´-DMTr-U (U-3-O, 1.0 mmol, 1.0 eq.) was added to a dry mixed solvent (5 mL dichloromethane and 5 mL acetonitrile), and the temperature was maintained at 0 °C. Then, 174 mg of lithium bromide (2.0 mmol, 2.0 eq.) was added, and the mixture was stirred for 5 minutes. Subsequently, 0.30 mL of DBU (2.0 mmol, 2.0 eq.) and 0.18 mL of N,N-dimethylphosphoaminodichloride (1.5 mmol, 1.5 eq.) dissolved in 1 mL of dry dichloromethane were added. The mixture was stirred at 0 °C for 40 minutes under nitrogen protection. The solvent was removed under reduced pressure. 50 mL of ethyl acetate was added to the residue, followed by washing with 30 mL of cold water. The organic phase was dried over sodium sulfate and concentrated under reduced pressure. Separation was performed by silica gel chromatography with a mixed solvent of dichloromethane / acetone / methanol as the mobile phase, yielding 456 mg of the target product U-3-1 (purity above 99%, yield 65%).
[0029] Furthermore, the following nucleotide monomers were prepared using the synthetic method described above: , ; in: Base is a nucleotide base containing a protecting group, such as adenine, guanine, cytosine, 5-methylcytosine, thymine, uracil, xanthine, hypoxanthine, pseudouracil, or N1-methylpseudorabies, and its derivatives. R can be hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, or aromatic. R1 and R2 are alkyl, alkenyl, alkynyl, cycloalkyl, or aromatic groups, respectively. R3 is an alkyl group (including methyl, ethyl, long-chain alkyl), cycloalkyl, alkenyl, cycloalkenyl, alkynyl, silyl (including trimethylsilyl, triethylsilyl, triisopropylsilyl, tert-butyldimethylsilyl, tert-butyldiphenylsilyl), silyloxymethylene, alkoxyalkyl, benzyl, or acyl (including acetyl, propionyl, butyryl, isobutyryl, benzoyl). R4 and R5 are hydrogen, halogen, alkyl, cycloalkyl, alkoxyalkyl, alkenyl, cycloalkenyl, alkynyl, cyano, azide, amino (amino), mercapto, alkyl mercapto, selenyl, alkyl selenyl, etc., respectively.
[0030] Furthermore, the following nucleotide monomers were prepared using the synthetic method described above: , ; in: Base is a nucleotide base containing a protecting group, such as adenine, guanine, cytosine, 5-methylcytosine, thymine, uracil, xanthine, hypoxanthine, pseudouracil, or N1-methylpseudorabies, and its derivatives. PG is triphenylmethyl (Tr), 4-methoxytriphenylmethyl (MMTr), 4,4'-dimethoxytriphenylmethyl (DMTr), 4,4',4''-trimethoxytriphenylmethyl (TMTr), allyl, allyloxycarbonyl, benzyl, acyl, silyl (including trimethylsilyl, tert-butyldimethylsilyl or tert-butyldiphenylsilyl). R can be alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkoxyalkyl, or aromatic. R1 and R2 are alkyl, alkenyl, alkynyl, cycloalkyl, or aromatic groups, respectively. R3 is an alkyl group (including methyl, ethyl, long-chain alkyl), cycloalkyl, alkenyl, cycloalkenyl, alkynyl, silyl (including trimethylsilyl, triethylsilyl, triisopropylsilyl, tert-butyldimethylsilyl, tert-butyldiphenylsilyl), silyloxymethylene, alkoxyalkyl, benzyl, or acyl (including acetyl, propionyl, butyryl, isobutyryl, benzoyl). R4 and R5 are hydrogen, halogen, alkyl, cycloalkyl, alkoxyalkyl, alkenyl, cycloalkenyl, alkynyl, cyano, azide, amino (amino), mercapto, alkyl mercapto, selenyl, alkyl selenyl, etc., respectively.
[0031] Cross-linked polystyrene (PS) was used as the support for solid-phase synthesis. 0.050 g of the modified solid-phase synthesis resin was weighed and added to a solid-phase synthesis tube. 2.0 mL of NMP was added, and the mixture swelled at room temperature for 2 hours, then the solution was drained by filtration. The resin was washed with 3.0 mL of dichloromethane, and this washing process was repeated three times to begin solid-phase synthesis.
[0032] The monomers introduced in solid-phase synthesis are phosphoramide P(III) and phosphoramide P(V).
[0033] The process conditions for phosphorus amide monomers are as follows: Reagents and monomers: Prepare a 0.15 mol / L monomer / acetonitrile solution; the deprotecting agent for DMTr (or Tr) is a 5% dichloroacetic acid / toluene solution (v / v); the activator is a 0.25 mol / L 5-ethylthiotetrazole / acetonitrile solution; the oxidizing agent is a 0.05 mol / L iodine solution of water / pyridine (10 / 90, v / v); the sulfiding agent is a 3% hydroxanthin / pyridine solution; capping agent A is a 10% acetic anhydride / acetonitrile solution (v / v), and capping agent B is a 1-methylimidazolium / pyridine / tetrahydrofuran solution (16 / 10 / 74, v / v / v).
[0034] The operational sequence for the solid-phase synthesis of phosphorous amide monomers is as follows: 1) Deprotection: 5% dichloroacetic acid toluene solution was used to remove the DMTr protecting group, followed by washing with acetonitrile.
[0035] 2) Coupling: Using 0.25 mol / L 5-ethylthiotetrazole as the activator, according to the sequence design, nucleotide monomers / acetonitrile solutions were fed into the cycle for coupling, followed by rinsing with acetonitrile.
[0036] 3) Oxidation / Sulfidation: P(III) was oxidized using a 0.05 mol / L iodine solution in water / pyridine (v / v, 90 / 10) as the oxidant, followed by rinsing with acetonitrile. P(III) was sulfided using a 3% hydroflavin pyridine solution as the sulfiding agent, followed by rinsing with acetonitrile.
[0037] 4) Capping: Capping agent A and capping agent B are used as capping reagents to protect the unreacted active groups, followed by rinsing with acetonitrile.
[0038] The process conditions for applying phosphoramide monomers to the solid-phase synthesis of oligonucleotides differ from those for the phosphoramide monomers described above as follows: Coupling solvent: 2.303 g of N-ethylmorpholine was diluted to 50 mL with 1,3-dimethyl-2-imidazolidinone (DMI) to obtain an N-ethylmorpholine DMI solution (0.40 mol / L), which was used as the coupling solvent.
[0039] Lysis buffer: Weigh 0.154 g of dithiothreitol, add 5 mL of N-methyl pyrrolidone (NMP) to dissolve, add 0.739 g of triethylamine, and dilute to 10 mL with NMP to obtain an NMP solution containing 0.10 mol / L dithiothreitol and 0.73 mol / L triethylamine, which is the lysis buffer. Prepare fresh before use.
[0040] The solid-phase synthesis process of phosphoramide monomers includes: Following the base sequence of the target sequence, nucleotide monomers were coupled one by one through a cyclical process of de-DMTr, neutralization, washing, coupling, neutralization, and washing. After the last monomer molecule was coupled, the terminal DMTr was removed, and 3.0 mL of p-methoxytriphenylmethyl chloride end-capping solution (0.32 mol / L) was added to the reaction tube. After reacting at 45 °C for 90 minutes, the reaction solution was drained, and the tube was washed 8 times with 4.0 mL of NMP each time.
[0041] Repeat the above operations according to the set sequence to obtain the oligonucleotide product of the target sequence.
[0042] Deprotection involves transferring the solid-phase support loaded with the oligonucleotide product into a reactor, adding concentrated ammonia (28%), controlling the temperature at 60 °C for 12 hours of ammonolysis, cooling to room temperature, filtering, washing the solid with a mixture of purified water and ethanol, combining the filtrates, and concentrating under reduced pressure at low temperature to obtain the crude oligonucleotide product with the designed sequence.
[0043] Purification involves dissolving the deprotected crude product in purified water, purifying it using HPLC, collecting the product peak solution, and then concentrating and lyophilizing the product peak solution under reduced pressure to obtain the final product.
[0044] The above solid-phase synthesis methods are also applicable to monomers protected by Tr, MMTr, and TMTr.
[0045] In examples of solid-phase synthesis, the nucleotide monomers used are represented by the following structures: , , , , , , , , , .
[0046] Example 5 This embodiment describes an oligonucleic acid with a phosphoramide-modified nucleotide structure. The nucleotide monomers loaded on the solid support are T-1-0, and the phosphoramide-modified nucleotide monomers are U-1-1 and U-4-1.
[0047] The synthesis reaction formula is ; Methods for synthesizing oligonucleotides with phosphoramide-modified nucleotide structures include: Monomer T-1-0 was loaded onto cross-linked polystyrene (PS). O3'-DMTr was removed using a 5% dichloroacetic acid-toluene solution. After washing with acetonitrile, monomer U-1-1 was pumped in for coupling. The system was then capped, and N3'-DMTr was removed using a 5% dichloroacetic acid-toluene solution. After washing with acetonitrile, monomer U-4-1 was pumped in for coupling, and O3'-DMTr was removed using a 5% dichloroacetic acid-toluene solution.
[0048] After ammonolysis and deprotection treatment, the crude product of the loaded oligonucleotide molecule was concentrated under reduced pressure and purified by HPLC. The main fraction was collected, concentrated, and freeze-dried to obtain the product, which was then confirmed to be the nucleic acid molecule of the target sequence.
[0049] Example 6 This embodiment describes an oligonucleic acid with a phosphoramide-modified nucleotide structure. The nucleotide monomers loaded on the solid support are T-1-0 and the phosphoramide-modified nucleotide monomers are U-2-1.
[0050] The synthesis reaction formula is ; Methods for synthesizing oligonucleotides with phosphoramide-modified nucleotide structures include: Monomer T-1-0 was loaded onto cross-linked polystyrene (PS). O3'-DMTr was removed using a 5% dichloroacetic acid-toluene solution. After washing with acetonitrile, monomer U-2-1 was pumped in for coupling. The system was then capped, and N3'-DMTr was removed using a 5% dichloroacetic acid-toluene solution. After washing with acetonitrile, monomer U-2-1 was pumped in for coupling, and N3'-DMTr was removed using a 5% dichloroacetic acid-toluene solution.
[0051] After ammonolysis and deprotection treatment, the crude product of the loaded oligonucleotide molecule was concentrated under reduced pressure and purified by HPLC. The main fraction was collected, concentrated, and freeze-dried to obtain the product, which was then confirmed to be the nucleic acid molecule of the target sequence.
[0052] Example 7 This embodiment describes an oligonucleic acid with a phosphoramide-modified nucleotide structure. The nucleotide monomers loaded on the solid support are T-1-0, the phosphoramide-modified nucleotide monomers are U-1-1, and the nucleotide phosphorylate is Af-1.
[0053] The synthesis reaction formula is ; Methods for synthesizing oligonucleotides with phosphoramide-modified nucleotide structures include: Monomer T-1-0 was loaded onto cross-linked polystyrene (PS). O3'-DMTr was removed using a 5% dichloroacetic acid-toluene solution. After washing with acetonitrile, monomer U-1-1 was pumped in for coupling. The system was then capped, and N3'-DMTr was removed using a 5% dichloroacetic acid-toluene solution. After washing with acetonitrile, monomer Af-1 was pumped in for coupling, followed by iodine / pyridine oxidation, and O3'-DMTr was removed using a 5% dichloroacetic acid-toluene solution.
[0054] After ammonolysis and deprotection treatment, the crude product of the loaded oligonucleotide molecule was concentrated under reduced pressure and purified by HPLC. The main fraction was collected, concentrated, and freeze-dried to obtain the product, which was then confirmed to be the nucleic acid molecule of the target sequence.
[0055] Example 8 This embodiment describes an oligonucleic acid with a phosphoramide-modified nucleotide structure. The nucleotide monomers loaded on the solid support are T-1-0, and the phosphoramide-modified nucleotide monomers are U-3-1 and U-4-1.
[0056] The synthesis reaction formula is ; Methods for synthesizing oligonucleotides with phosphoramide-modified nucleotide structures include: Monomer T-1-0 was loaded onto cross-linked polystyrene (PS). O3'-DMTr was removed using a 5% dichloroacetic acid-toluene solution. After washing with acetonitrile, monomer U-3-1 was pumped in for coupling. The system was then capped, and N3'-DMTr was removed using a 5% dichloroacetic acid-toluene solution. After washing with acetonitrile, monomer U-4-1 was pumped in for coupling. The system was then capped, and O3'-DMTr was removed using a 5% dichloroacetic acid-toluene solution.
[0057] After ammonolysis and deprotection treatment, the crude product of the loaded oligonucleotide molecule was concentrated under reduced pressure and purified by HPLC. The main fraction was collected, concentrated, and freeze-dried to obtain the product, which was then confirmed to be the nucleic acid molecule of the target sequence.
[0058] Example 9 This embodiment is an oligonucleotide with a phosphoramide-modified nucleotide structure. In the preparation process, the nucleotide monomer loaded on the solid support is U-5-0, the phosphoramide-modified nucleotide monomer is U-1-1, and the 3'-terminal phosphoramide monomer is T-5-1.
[0059] The structural formula of oligonucleotides is ; Methods for synthesizing oligonucleotides with phosphoramide-modified nucleotide structures include: Monomer U-5-0 was loaded onto cross-linked polystyrene (PS). O3'-DMTr was removed using a 5% dichloroacetic acid-toluene solution. After washing with acetonitrile, monomer U-1-1 was pumped in for coupling. After capping, N3'-DMTr was removed using a 5% dichloroacetic acid-toluene solution. After washing with acetonitrile, monomer U-1-1 was pumped in, and this cycle was repeated five times. After capping, N3'-DMTr was removed using a 5% dichloroacetic acid-toluene solution. After washing with acetonitrile, monomer T-5-1 was pumped in for coupling. Following solid-load shearing, deprotection, HPLC purification, and desalting, a phosphoramide-modified oligonucleotide molecule with the desired sequence structure was obtained, denoted as ON7-PN6-1.
[0060] Example 10 This comparative example is an oligonucleotide with the same base sequence as ON7-PN6-1. During preparation, the nucleotide monomer loaded on the solid-phase support was T-2-0, and the nucleotide monomer used was nucleotide phosphorylate U-6-1. The structural formula of the oligonucleotide is as follows: This oligonucleotide, denoted as ON7, was synthesized using a conventional solid-phase synthesis method, with nucleotides coupled in a 3' to 5' orientation.
[0061] Example 11 The isoelectric points of the oligonucleotides ON7-PN6-1 prepared in Example 9 and ON7 prepared in Example 10 were tested. The results showed that the isoelectric point of the oligonucleotide ON7 was 5.03 (±0.12), and the isoelectric point of the phosphoramide-modified oligonucleotide ON7-PN6-1 was 7.39 (±0.23). It can be seen that phosphoramide modification can improve the binding ability of the modified oligonucleotide to anions.
[0062] Example 12 The stability of ON7-PN6-1 prepared in Example 9 and ON7 prepared in Example 10 in human serum and human liver microsomes were tested respectively.
[0063] Test results show that: The oligonucleotide molecule ON7 without phosphoramide modification showed significant degradation, with the proportion of undegraded nucleic acid sequences falling below 5% after 4 hours. In contrast, the proportion of undegraded oligonucleotide chains ON7-PN6-1 containing phosphoramide-modified nucleotides was greater than 70% after 18 hours of incubation in human serum or human liver microsomes, indicating that the modified oligonucleotide molecule has a stronger resistance to biological enzyme degradation.
[0064] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, and not to limit them. Although the present invention has been described in detail with reference to the foregoing embodiments, those skilled in the art should understand that modifications can still be made to the technical solutions described in the foregoing embodiments, or equivalent substitutions can be made to some or all of the technical features therein. Such modifications or substitutions do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present invention, and they should all be covered within the scope of the claims and specification of the present invention.
Claims
1. The synthesis of a 3´-amino-5´-nucleotide phosphoramide and its application in oligonucleotides, characterized in that, The phosphoramide-modified oligonucleotide includes at least one of the nucleotide structural units shown in Formula I, Formula II, Formula III, or Formula IV: ...Formula I; ...Formula II; In Equations I and II: Base is a nucleotide base or its derivative, wherein the nucleotide base is adenine, guanine, cytosine, 5-methylcytosine, thymine, uracil, xanthine, hypoxanthine, pseudouracil, or N1-methylpseudorabies, etc., or its derivatives. R can be hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, or aromatic. R1 and R2 are alkyl, alkenyl, alkynyl, cycloalkyl, or aromatic groups, respectively; R3 is hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, silyl, silyloxymethylene, alkoxyalkyl, benzyl, or acyl. ...Formula III; ...Form IV; In Equations III and IV: Base is a nucleotide base or its derivative, wherein the nucleotide base is adenine, guanine, cytosine, 5-methylcytosine, thymine, uracil, xanthine, hypoxanthine, pseudouracil, or N1-methylpseudorabies, etc., or its derivatives. R can be hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, or aromatic. R1 and R2 are alkyl, alkenyl, alkynyl, cycloalkyl, or aromatic groups, respectively; R4 and R5 are hydrogen, halogen, alkyl, cycloalkyl, alkoxyalkyl, alkenyl, cycloalkenyl, alkynyl, cyano, azide, amino (amino), mercapto, alkyl mercapto, selenyl, alkyl selenyl, etc., respectively.
2. The synthesis of a 3'-amino-5'-nucleotide phosphoramide according to claim 1 and its application in oligonucleotides, characterized in that, The oligonucleotides with the phosphoramide-modified structures are synthesized using nucleotide phosphoramide monomers represented by Formula V or Formula VI: ...Form V; In formula V: Base is a nucleotide base containing a protecting group, such as adenine, guanine, cytosine, 5-methylcytosine, thymine, uracil, xanthine, hypoxanthine, pseudouracil, or N1-methylpseudorabies, and its derivatives. PG is triphenylmethyl, 4-methoxytriphenylmethyl, 4,4'-dimethoxytriphenylmethyl, 4,4',4''-trimethoxytriphenylmethyl, allyl, allyloxycarbonyl, benzyl, acyl, trimethylsilyl, tert-butyldimethylsilyl or tert-butyldiphenylsilyl. R can be hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, or aromatic. R1 and R2 are alkyl, alkenyl, alkynyl, cycloalkyl, or aromatic groups, respectively; R3 is a alkyl, cycloalkyl, alkoxyalkyl, carbonylalkyl, benzyl (Bn), benzoyl (Bz), acetyl or propionyl, acyl, alkenyl, cycloalkenyl, alkynyl, allyl, allyloxycarbonyl, trimethylsilyl, triethylsilyl, triisopropylsilyl, tert-butyldimethylsilyl or tert-butyldiphenylsilyl, etc. ……Formula VI; In formula VI: Base is a nucleotide base containing a protecting group, such as adenine, guanine, cytosine, 5-methylcytosine, thymine, uracil, xanthine, hypoxanthine, pseudouracil, or N1-methylpseudorabies, and its derivatives. PG is triphenylmethyl, 4-methoxytriphenylmethyl, 4,4'-dimethoxytriphenylmethyl, 4,4',4''-trimethoxytriphenylmethyl, allyl, allyloxycarbonyl, benzyl, acyl, trimethylsilyl, tert-butyldimethylsilyl or tert-butyldiphenylsilyl. R can be hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, or aromatic. R1 and R2 are alkyl, alkenyl, alkynyl, cycloalkyl, or aromatic groups, respectively; R4 and R5 are hydrogen, halogen, alkyl, cycloalkyl, alkoxyalkyl, alkenyl, cycloalkenyl, alkynyl, cyano, azide, amino (amino), mercapto, alkyl mercapto, selenyl, alkyl selenyl, etc., respectively.
3. The synthesis of a 3'-amino-5'-nucleotide phosphoramide according to claim 2 and its application in oligonucleotides, characterized in that, The nucleotide monomers include: 、 、 、 、 、 、 、 、 、 、 ， in: R can be hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, or aromatic. R1 and R2 are alkyl, alkenyl, alkynyl, cycloalkyl, or aromatic groups, respectively; R3 is an alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, silyl, silyloxymethylene, alkoxyalkyl, benzyl, or acyl group.
4. The synthesis of a 3'-amino-5'-nucleotide phosphoramide according to claim 2 and its application in oligonucleotides, characterized in that, The nucleotide monomers include: 、 、 、 、 、 、 、 、 、 、 ， in: R can be hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, or aromatic. R1 and R2 are alkyl, alkenyl, alkynyl, cycloalkyl, or aromatic groups, respectively.
5. The synthesis of a 3'-amino-5'-nucleotide phosphoramide according to claim 2 and its application in oligonucleotides, characterized in that, The nucleotide monomers include: 、 、 、 、 、 、 、 、 、 、 ， in: R can be hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, or aromatic. R1 and R2 are alkyl, alkenyl, alkynyl, cycloalkyl, or aromatic groups, respectively.
6. The phosphoramide-modified oligonucleic acid according to any one of claims 3 to 5, characterized in that, In the nucleotide monomer, 4,4'-dimethoxytriphenylmethyl (DMTr) is replaced with triphenylmethyl (Tr), 4-methoxytriphenylmethyl (MMTr), or 4,4',4''-trimethoxytriphenylmethyl (TMTr).
7. The synthesis of a 3'-amino-5'-nucleotide phosphoramide according to claim 2 and its application in oligonucleotides, characterized in that, The nucleotide monomer is prepared by reacting a nucleotide molecule containing a protecting group (N3') with phosphoramide dichloride.
8. The synthesis of a 3'-amino-5'-nucleotide phosphoramide according to claim 1 and its application in oligonucleotides, characterized in that, The modified oligonucleotides include nucleotide structures modified with 3´-amino and 5´-phosphoramide, which not only improves the biostability and anti-enzymatic degradation activity of the oligonucleotides, but also improves the binding performance between the modified oligonucleotide molecules and anions.
9. The synthesis process of the phosphoramide-modified oligonucleic acid according to any one of claims 1 to 8, characterized in that, In solid-phase synthesis, the coupling of nucleotide monomers occurs along a 5' to 3' direction, and the synthetic process includes the following steps: (a) Load nucleotide monomers onto a solid support, then remove the 3' protecting group from the nucleotide monomers and wash them; (b) A nucleotide monomer is pumped into the washed system for coupling, followed by capping, removal of the 3' protecting group on the nucleotide monomer, and washing. The nucleotide monomer is a phosphoramide nucleotide monomer or a phosphorous acid nucleotide monomer. If the nucleotide monomer is a phosphorous acid nucleotide monomer, after the coupling reaction, the trivalent phosphite is converted to a pentavalent phosphate ester by oxidation or sulfidation, followed by capping, removal of the 3' protecting group on the nucleotide monomer, and washing. (c) Repeat step (b) to obtain oligonucleotides with phosphoramide-modified nucleotide structures.
10. The oligonucleic acid according to claim 1, characterized in that, The oligonucleotide is selected from any one or a combination of at least two of small interfering nucleotides, antisense oligonucleotides, microRNAs, small activating RNAs, small guide RNAs, transfer RNAs, and aptamers.